The global liver cancer therapeutics market size attained a value of USD 2.50 Billion in 2024, driven by the rising prevalence of liver cancer and the growing demand for effective treatment options across the globe. The market is anticipated to grow at a CAGR of 19.85% during the forecast period of 2025-2034 to reach a value of USD 15.29 Billion by 2034.
Base Year
Historical Period
Forecast Period
Compound Annual Growth Rate
19.85%
Value in USD Billion
2025-2034
Liver Cancer Therapeutics Market Outlook
*this image is indicative*
Cancer is a life-threatening disease where the cells of a part of our body go out of control and starts growing rapidly. This disease, when effects and starts growing in the liver, is known as liver cancer or hepatic cancer. Although early signs of liver cancer are usually non-existent, they may include unconditional weight loss, appetite loss, upper abdominal pain, nausea, and vomiting, abdominal swelling, jaundice, general weakness and fatigue.
The EMR’s report titled “Liver Cancer Therapeutics Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Cancer Type
Market Breakup by Therapy Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channels
Market Breakup by End User
Market Breakup by Region
The market for liver cancer therapeutics, based on therapy types, can be divided into ablation therapy, embolization therapy, radiation therapy, targeted therapy, immunotherapy, and chemotherapy.
Among the various types of therapies, targeted therapy is expected to cover a major portion of the market owing to the increasing demand for targeted therapy due to its various advantages. Targeted therapies are utilised to directly target tumour cells while eliminating the chances of acquiring side effects on the surrounding normal cells. The increasing utilisation of targeted therapy can be a major driving factor for the segment and market value.
Based on the route of administration, the market can be divided into oral and intravenous administration. The intravenous route is the most widely by healthcare professionals as a method of administration for cancer therapy methods such as chemotherapy.
Healthcare professionals utilise this route of administration to administer multiple doses of medication or give medicated infusions. This route eliminates the need to inject a needle or tool multiple times to administer the same medicine and allows the medication to directly reach blood circulation.
Oral administration is growing in demand due to it being a non-invasive method of administration. This mode of administration provides multiple benefits including patient comfort, cost-effectiveness, and easy large-scale manufacturing of the medication. The increasing patient preference for oral administration can prople market growth
The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans.
Bayer AG, founded in 1863, and headquartered in Leverkusen, Germany, is a multinational pharmaceutical and biotechnology company. It is one of the world’s largest pharmaceutical companies with a speciality in various fields including pharmaceuticals, agricultural chemicals, seeds and biotechnology products, life sciences, and consumer health. The products developed by the company are applied to tackle some of the biggest challenges including global population growth, an ageing society, and to create sustainability.
Pfizer Inc. is an American pharmaceutical and biotechnology company. The company is headquartered in New York, United States, and it has been operating in the industry since 1849. The company works with an aim to introduce treatment solutions in the healthcare sector to create a healthier world. The company has expertise in utilising the science and global resources to improve healthcare around the world. The company is actively providing safe and effective medicines and healthcare services to underserved groups of people.
Bristol Myers Squibb Company is a multinational pharmaceutical company, headquartered in New York City, United States. The company was established in the year 1887 and has been operating in the field of biotechnology, pharmaceuticals, healthcare, and research and development, among others, to become one of the leading companies in the world.The company has made multiple advancements in various medical fields such as oncology, haematology, immunology, and cardiovascular disease. Through their diverse array of products and innovative platforms, the company can assist patients in receiving better therapy at any stage of life.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other market players include Exelixis, Inc., Merck & Co., Inc., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd, among others.
Liver Cancer Therapeutics Market Size
Liver Cancer Therapeutics Market Trends
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is expected to grow at a CAGR of 19.85% during the forecast period of 2025-2034.
The market is driven by the growing prevalence of liver cancer among people, especially the ageing population, around the world and the simultaneously rising demand for cancer therapeutics.
The increasing investment by market players and the government to introduce innovative solutions in the market and the rising demand for targeted therapy for cancer treatment can aid the market development.
The regional markets include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The types of liver cancers found in people include hepatocellular carcinoma, cholangio carcinoma, and hepatoblastoma, among others.
The market provides various therapy types including ablation therapy, embolization therapy, radiation therapy, targeted therapy, immunotherapy, and chemotherapy.
The different services available in the market include oral and intravenous administration.
The different distribution channels available in the market include hospital pharmacies, retail pharmacies, and online pharmacies.
The key players in the market include Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Exelixis, Inc., Merck & Co., Inc., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd, among others.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Cancer Type |
|
| Breakup by Therapy Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channels |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
